Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.57
▼ $0.02 (-0.4%)
Market data updated: 09/20 06:39 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$318.51M
Day Range
$5.53 - $5.84
52-Week Range
$4.00 - $7.65
Beta
—
Next Earnings
10.11.2026
Support
$5.22
Resistance
$7.65
ABEO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-1.2% (1Y)
Strengths: 13/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 165.2%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$21.98 vs. price $5.57 (-494.7%)
Fair Value
Signal tension
Growth scores strong (60/100), but fair-value analysis scores this stock as relatively expensive (43/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
52
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
60
Quality
47
Value
43
Momentum
26
Risk
46
Sentiment
100
Fundamental
65
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Abeona Therapeutics Inc. has focused on its progress with **Zevaskyn®**, its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company reported a **31% revenue surge** in Q2 2026, driven by expanded patient treatment (five in Q2, totaling 12 thus far) and improved market access, including CMS NTAP status. Despite early manufacturing challenges, Abeona is scaling its treatment network while preparing for broader commercialization. Additionally, recent announcements highlight **investor conferences** and **new employee equity grants** to attract talent.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Abeona Therapeutics Inc.. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
49
Psychology
31
Fundamentals
65
Technical
26
Valuation
43
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
-3%
Market Narrative
56
Fundamental Reality
49
Narrative Gap
+7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ABEO’s psychology score (28) reflects a neutral, *herding*-dominated state where traders appear to follow sector trends rather than act on conviction. The narrative gap (5-point divergence) suggests a disconnect between market perception (optimistic) and technical reality (subdued momentum). Key uncertainty lies in whether herding persists as peers stabilize or if ABEO’s underperformance triggers selective disengagement. The lack of extreme bias (e.g., panic or euphoria) implies cautious, reactive positioning—waiting for clearer signals before decisive action.
Updated: 09/08/2026, 10:19 PM
👥 What the crowd believes
"ZEVASKYN revenue surges 31% despite manufacturing hiccups and patient cancellations"
"Five patients treated in 2Q26; 12 patients treated in total thus far"
"Secures CMS NTAP status to bolster market access"
"Oppenheimer lowers price target from $22 to $21 while maintaining Outperform rating"
📈 19D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 88/100
🔴 Weakest match
Morgan Housel — 31/100
🗣️ Why do they disagree?
Based on Peter Lynch’s documented growth‑focused principles, the model estimates the stock is a strong growth candidate, while Benjamin Graham’s defensive criteria also rate it favorably, reflecting its apparent safety margin. In contrast, Fisher’s emphasis on high‑quality, sustainable growth and Livermore’s trend‑following rule lead to low scores, signalling concerns about the company’s profit quality and price momentum. Investors like Bagehot and Nelson, who prioritize liquidity and cyclical positioning, assign higher marks, whereas Marks, Loeb, and the efficient‑market view express mixed or modest confidence due to perceived valuation and cycle considerations. Finally, the lower scores from Vebren, Housel, and the enterprising Graham lens highlight worries about volatility, speculative growth translation, and the lack of a deep discount, resulting in a more cautious overall assessment.
Peter Lynch
One Up on Wall Street (1989)
🟢 88
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 82
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 80
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 76
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 72
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 66
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 62
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 49
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 48
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 42
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 36
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 36
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
73.7%
Operating Margin
-1536.9%
Net Margin
1223.1%
EBITDA Margin
-1493.1%
ROE
44.7%
ROA
32.4%
ROIC
—
EPS
$1.34
Cash
$78.44M
Total Debt
$20.04M
Current Ratio
6.93
Debt/Equity
0.13
How is Fair Value calculated? →
Current Price
$5.57
Estimated Fair Value (DCF)
-$21.98
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-494.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
8.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 8.2% | $-91.23M | $-83.70M |
| 2 | 6.8% | $-97.42M | $-82.00M |
| 3 | 5.4% | $-102.65M | $-79.26M |
| 4 | 3.9% | $-106.68M | $-75.57M |
| 5 | 2.5% | $-109.35M | $-71.07M |
Base FCF (last actual year)
$-84.30M
Terminal Value
$-1.72B
Present Value of Terminal Value
$-1.12B
Enterprise Value
$-1.51B
Net Debt
$-58.40M
Equity Value
$-1.45B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.41
Tangible Book Value per Share (Tangible NAV)
$2.41
Sentiment based on basic keywords (not AI) — 11 positive, 8 neutral, 1 negative out of the last 20 articles.
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 21.8.2026
Insider Monkey · 21.8.2026
Yahoo · 17.8.2026
GuruFocus.com · 17.8.2026
Yahoo · 17.8.2026
Zacks Small Cap Research · 17.8.2026
Abeona Therapeutics Inc. (ABEO) currently has a StockIQ AI score of 52/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ABEO currently scores 52/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ABEO's estimated fair value is -$21.98, which is 494.7% below the current price of $5.57. This is one valuation model among several signals in the fair-value category, not a price target.
ABEO's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 165.2%; Net income growth: 211.7%; Return on equity (ROE): 44.7% — strong.
Based on the real signals StockIQ computed: Estimated fair value: -$21.98 vs. price $5.57 (-494.7%); Operating margin: -1536.9% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for ABEO.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 24 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Alvino Mark | Open Market Sale | 1.9.2026 | 15,000 | -15,000 | $5.86 |
| Vazzano Joseph Walter | Open Market Sale | 21.7.2026 | 1,478 | -1,478 | $6.53 |
| Vazzano Joseph Walter | Open Market Sale | 21.7.2026 | 492,079 | -1,478 | $6.53 |
| Vasanthavada Madhav | Open Market Sale | 9.7.2026 | 12,606 | -12,606 | $6.96 |
| O'Malley Brendan M. | Open Market Sale | 9.7.2026 | 12,050 | -12,050 | $6.96 |
| Seshadri Vishwas | Open Market Sale | 9.7.2026 | 67,971 | -67,971 | $6.96 |
| Vazzano Joseph Walter | Open Market Sale | 9.7.2026 | 24,880 | -24,880 | $6.96 |
| Vazzano Joseph Walter | Open Market Sale | 9.7.2026 | 493,557 | -24,880 | $6.96 |
| Seshadri Vishwas | Open Market Sale | 9.7.2026 | 1,306,108 | -67,971 | $6.96 |
| O'Malley Brendan M. | Open Market Sale | 9.7.2026 | 427,953 | -12,050 | $6.96 |
| Vasanthavada Madhav | Open Market Sale | 9.7.2026 | 290,623 | -12,606 | $6.96 |
| Alland Leila | Open Market Sale | 30.6.2026 | 11,000 | -11,000 | $5.92 |
| Alland Leila | Open Market Sale | 30.6.2026 | 162,614 | -11,000 | $5.92 |
| Vasanthavada Madhav | Other Transaction | 16.6.2026 | 222 | -222 | $5.67 |
| Silverstein Christine Berni | Open Market Sale | 15.6.2026 | 18,160 | -18,160 | $5.71 |
| Silverstein Christine Berni | Open Market Sale | 15.6.2026 | 119,562 | -18,160 | $5.71 |
| Seshadri Vishwas | Open Market Sale | 9.6.2026 | 31,916 | -31,916 | $5.30 |
| Vazzano Joseph Walter | Open Market Sale | 9.6.2026 | 25,646 | -25,646 | $5.39 |
| Vasanthavada Madhav | Open Market Sale | 9.6.2026 | 5,450 | -5,450 | $5.30 |
| Vazzano Joseph Walter | Open Market Sale | 9.6.2026 | 13,421 | -13,421 | $5.30 |
| O'Malley Brendan M. | Open Market Sale | 9.6.2026 | 6,305 | -6,305 | $5.30 |
| Vazzano Joseph Walter | Open Market Sale | 9.6.2026 | 544,083 | -13,421 | $5.30 |
| Vazzano Joseph Walter | Open Market Sale | 9.6.2026 | 518,437 | -25,646 | $5.39 |
| Seshadri Vishwas | Open Market Sale | 9.6.2026 | 1,374,079 | -31,916 | $5.30 |
| O'Malley Brendan M. | Open Market Sale | 9.6.2026 | 440,003 | -6,305 | $5.30 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
15,157,188 shares short as of 2026-08-31 · vs. 13,639,416 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.9% of trading volume this week was short selling, vs. 63.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology